Impact of HIV-1 and Aging on Mucosal Vaccine Responses
| Status: | Recruiting |
|---|---|
| Conditions: | Infectious Disease, HIV / AIDS, HIV / AIDS, HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 21 - 75 |
| Updated: | 1/27/2019 |
| Start Date: | January 18, 2017 |
| End Date: | June 1, 2022 |
| Contact: | Mandy N Borgeson |
| Email: | mandy.borgeson@ucdenver.edu |
| Phone: | 720-788-8318 |
The purpose of this study is to learn more about both HIV-1 infection and advancing age,
alone and in combination, and their association with increased risk of serious infection and
impaired response to the Prevnar 13 vaccine.
alone and in combination, and their association with increased risk of serious infection and
impaired response to the Prevnar 13 vaccine.
Inclusion Criteria:
- Veterans only (accessibility to non-veterans pending)
- Age 21-45 or 55-75 Years Old
- Have not received pneumococcal vaccine Prevnar PCV-13
- Able to attend 2-3 study visits over 1 month
HIV+:
-Undetectable Viral load
HIV negative controls:
-no history or risks for HIV infection
Exclusion Criteria:
- Spleen removed
- Chronic Kidney disease (creatinine ≥ 2.0 mg/dL)
- Lymphoma or leukemia
- Currently taking: Corticosteroids (prednisone, medrol, etc), Chemotherapy,
Immunosuppressive medication (cyclosporine, methotrexate, azathioprine, infliximab,
adalimumab, rituximab, etanercept, etc), or illicit drugs (methamphetamine, cocaine,
crack, or heroin)
We found this trial at
1
site
1700 North Wheeling Street
Aurora, Colorado 80045
Aurora, Colorado 80045
Principal Investigator: Edward N Janoff, MD
Phone: 720-788-8318
Click here to add this to my saved trials
